Cadence Molecular Sciences (OpenEye)—a business unit of Cadence (Nasdaq: CDNS)–is excited to announce the Orion® Molecular Design Platform is now available on the Cadence® Millennium™ M2000 Supercomputer in Cadence OnCloud, a state-of-the-art solution offering a tightly co-optimized software and hardware stack, that ensures drug discovery jobs run reliably and at scale.
Compute resources, including GPUs, CPUs, and storage, are required components for processing critical tasks and decision-making in drug discovery. Demand for resources has increased dramatically, affecting several industries, including life sciences. Constraints on GPU availability have caused backups, especially related to building artificial intelligence (AI) models. Cadence Molecular Sciences aims to make these computational resources readily available to allow drug design to proceed unhindered.
“Orion on Millennium M2000 Supercomputer in Cadence OnCloud delivers robust and reliable computation to any therapeutics project,” said Geoff Skillman, Vice President, Research & Development, Cadence Molecular Sciences. “With the latest accelerated compute, FastROCS can screen 50 million molecules per second, achieving more than 800x speedup, enabling faster and more efficient drug discovery.”
Screening molecules on the Millennium M2000 Supercomputer returns results in less than four minutes as compared to the previously required two days.
Orion is a cloud-based platform combining state-of-the-art software, hardware and orchestration that powers the computational design of molecules. The software enables a wide range of calculations at massive scale, including ligand-based and structure-based virtual screening, molecular dynamics (MD) simulations, free energy prediction, quantum mechanics calculations and sequence analyses. It is highly optimized for drug discovery and customizable for enterprise computation at start-up biotechs through to the world’s largest pharmaceutical companies.
Treeline Biosciences, a biotechnology company that targets cancer and other serious conditions, recently renewed its contract with Cadence Molecular Sciences for Orion Managed Service and is the first customer to gain access to Millennium M2000 Supercomputer in Cadence OnCloud.
“The Millennium M2000 Supercomputer accelerates the discovery of novel therapeutics for our clinical pipeline,” said Eric Manas, Senior Vice President of Medicine Design, Treeline Biosciences. “The seamless combination of Orion and dedicated accelerated compute in the cloud ensures we can focus on what matters the most—scientific decisions.”
Orion is available as a turn-key, software-as-a-service (SaaS) multi-tenant solution and also as a single-tenant, managed service platform. Orion Managed Service provides computational resources, data integration and a seamless experience for in-house development of customized methods, including artificial intelligence. In either case, Orion is packed with a combination of OpenEye software, high-quality third-party commercial software and open-source solutions to enable computational chemists the maximum flexibility to progress discovery projects.
To advance your projects with Orion and Millennium M2000 Supercomputer in Cadence OnCloud, please contact oe-sales@cadence.com.
Read the full Cadence Millennium M2000 Supercomputer news release.